

APPLICATIONS

Quantitative Analysis of Gamma-Hydroxybutyrate (GHB) in Whole Blood Using Fast SPE and LC-MS/MS

Shahana Huq and Matthew Brusius
Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA



Product Manager Sample Preparation

Matt Brusius is an avid ice hockey player. He likes skating backwards and taking slapshots from the point.

Introduction

As a drug of abuse, Gamma-hydroxybutyric Acid (GHB) is often overlooked in forensic toxicological analysis unless it is specifically requested in the screen. Testing for GHB can be difficult due to inaccurate/unreliable response in immunoassays or chromatographic screens and due to the stability of the compound. The time sensitive nature of this assay demands for an analytical procedure that is quick, efficient, and one that preserves the authenticity of the biological specimen. The goal of this application is to present a comprehensive method for the quantitation of GHB in human blood using solid phase extraction (SPE) in conjunction with LC-MS/MS analysis. A quick, two step sample preparation protocol combining protein precipitation (PP) with SPE was employed. The SPE method did not require any conditioning or equilibration of the SPE cartridge, thus allowing for significant time savings. A Luna[®] 3 μ m 150 x 2.0 mm HILIC LC column was utilized for chromatographic analysis, enabling direct injection of the extracted sample in a MS friendly 75% organic. The prescribed protocol circumvents the need for a dry down or reconstitution step and makes it quick and easy to implement in a laboratory workflow, all while providing accurate results.

Materials and Methods

Reagents and Chemicals

Analytical reference standards and internal standards were purchased from Cerilliant Corporation (Round Rock, TX, USA). Pooled human whole blood with disodium EDTA was purchased from BioreclamationIVT[®] (Westbury, NY). All other reagents and chemicals were purchased from Sigma-Aldrich[®] (St. Louis, MO). Ultrapure D.I water was obtained from Sartorius arium[®] comfort II, courtesy of Sartorius Corporation (Bohemia, NY).


SPE Protocol

Sample Pre-treatment

To 500 μ L whole blood add 100 μ L 5 % (w/v) ZnSO₄ and vortex 3-5 seconds. Add 1.5 mL of chilled (~0 °C) 90:10 Acetonitrile/Methanol while vortexing. Centrifuge samples at 6000 rpm for 5 minutes and then collect supernatant.

SPE Conditions

- 96-Well Plate:** Strata-X PRO, 30mg/well
Part No.: [8E-S536-TGA](#)
Load: Pass the supernatant collected from pre-treatment, apply vacuum and collect extract.
Direct Injection: 5 μ L of the above sample was injected directly on LC-MS/MS (bypass dry-down and reconstitution).



LC Conditions

Quantitative Analysis for GHB

Column:	Luna 3 μ m HILIC														
Dimensions:	150 x 2.0 mm														
Part No.:	00F-4449-B0														
Mobile Phase:	A: Acetonitrile B: 100 mM Ammonium Formate														
Gradient:	<table border="0"> <thead> <tr> <th>Time (min)</th> <th>% B</th> </tr> </thead> <tbody> <tr><td>0</td><td>20</td></tr> <tr><td>1</td><td>20</td></tr> <tr><td>1.5</td><td>50</td></tr> <tr><td>2</td><td>50</td></tr> <tr><td>2.01</td><td>20</td></tr> <tr><td>7</td><td>20</td></tr> </tbody> </table>	Time (min)	% B	0	20	1	20	1.5	50	2	50	2.01	20	7	20
Time (min)	% B														
0	20														
1	20														
1.5	50														
2	50														
2.01	20														
7	20														
Flow Rate	0.4 mL/min														
Injection Volume:	5 μ L														
IHPLC Instrument:	Agilent [®] 1260														
MS/MS Instrument:	SCIEX [®] API Triple Quad 4500 [™] , ESI Source (+)														

Qualitative Analysis for Phospholipids

Column:	Kinetex [®] 2.6 μ m C18												
Dimensions:	50 x 2.1 mm												
Part No.:	00B-4462-AN												
Mobile Phase:	A: 0.1 % Formic acid in Water B: 0.1 % Formic acid in Methanol												
Gradient:	<table border="0"> <thead> <tr> <th>Time (min)</th> <th>% B</th> </tr> </thead> <tbody> <tr><td>0</td><td>40</td></tr> <tr><td>0.5</td><td>95</td></tr> <tr><td>11.5</td><td>95</td></tr> <tr><td>11.51</td><td>40</td></tr> <tr><td>13.5</td><td>40</td></tr> </tbody> </table>	Time (min)	% B	0	40	0.5	95	11.5	95	11.51	40	13.5	40
Time (min)	% B												
0	40												
0.5	95												
11.5	95												
11.51	40												
13.5	40												
Flow Rate	0.4 mL/min												
Injection Volume:	1 μ L												
HPLC Instrument:	Agilent 1260												
MS/MS Instrument:	SCIEX API Triple Quad 4500, ESI Source (+)												

Table 1.
Retention time (RT) and MRM Transition for Analytes

Analyte	RT (min)	Q1	Q3
GHB	1.7	104.9	86.9 68.9
GHB-d6	1.7	111	93
Lyso PC	2.4	496.4	184.2
PC-1	6.7	760.7	184.2
PC-2	7.2	786.8	184.2

Table 2.
% Absolute Recovery of GHB from Extracted Whole Blood Sample (N=4) Using Strata[®]-X PRO SPE

Spiked Conc.	% Recovery	% CV
10.0 µg/mL	75 %	6.7 %

Figure 2.
Representative Chromatogram Showing Phospholipid Trace of Blood Matrix in pre (A) and post (B) SPE (Strata-X PRO) Extracted Sample.





Figure 1.
Representative Chromatogram of GHB Extracted Whole Blood Analyzed by a Luna[®] 3 µm 150 x 2.0 mm HILIC column




App ID 25616

Table 3.
Precision and Accuracy Data for QC Samples

Expected Conc. (µg/mL)	Sample	Replicates (N)	% CV	Accuracy
15	QC 1	4	11.4	104.2
75	QC 2	4	4.5	94.5

Figure 3.
Linearity Curve for GHB Extracted Blood Matrix over 1-300-fold Dynamic Concentration Range






App ID 25526

Results and Discussion

The developed HILIC LC conditions utilizes a Luna® 3µm HILIC column (**Figure 1**) and allows for direct injection of extracted samples, bypassing the time consuming dry-down and reconstitution steps, before injection. The method utilizes a protein precipitation followed by a quick sample pass-through SPE method. The resulting extract yields cleaner background (**Figure 2B**) by selective removal of phospholipids. This is very important because phospholipids can be responsible for unpredictable, inaccurate results in an analytical run as well as causing increased MS instrument down time. The absolute recovery and % CV for extracted blood matrix reported were 75 % and 6.7 % respectively (**Table 2**). The linear regression value (R=0.9994) of the extracted sample along with precision and accuracy data supports the sound extraction efficiency of the assay over 300-fold dynamic range (**Figure 3** and **Table 3**). The lowest point of linearity curve constructed was 1µg/mL, as the concentration range around that (< 5µg/mL) point generally is considered endogenous presence rather than GHB ingestion.

Ordering Information

Strata®-X PRO SPE

Format	Sorbent Mass	Part Number	Unit
Tube			
	10 mg	8B-S536-AAK	1 mL (100/box)
	30 mg	8B-S536-TAK	1 mL (100/box)
	30 mg	8B-S536-TBJ	3 mL (50/box)
	60 mg	8B-S536-UBJ	3 mL (50/box)
	200 mg	8B-S536-FBJ	3 mL (50/box)
	100 mg	8B-S536-ECH	6 mL (30/box)
	200 mg	8B-S536-FCH	6 mL (30/box)
	500 mg	8B-S536-HCH	6 mL (30/box)
96-Well Plate			
	10 mg/well	8E-S536-AGA	ea
	30 mg/well	8E-S536-TGA	ea
	60 mg/well	8E-S536-UGA	ea
96-Well Microelution Plate			
	2 mg/well	8M-S536-4GA	ea

Kinetex® Core-Shell LC Columns

2.6µm Minibore Columns (mm)						SecurityGuard™ ULTRA Cartridges†
Phases	30 x 2.1	50 x 2.1	75 x 2.1	100 x 2.1	150 x 2.1	3/pk
C18	00A-4462-AN	00B-4462-AN	00C-4462-AN	00D-4462-AN	00F-4462-AN	AJ0-8782
for 2.1 mm ID						

2.6µm MidBore™ Columns (mm)						SecurityGuard ULTRA Cartridges†
Phases	30 x 3.0	50 x 3.0	75 x 3.0	100 x 3.0	150 x 3.0	3/pk
C18	00A-4462-YO	00B-4462-YO	00C-4462-YO	00D-4462-YO	00F-4462-YO	AJ0-8775
for 3.0 mm ID						

1.7µm Minibore Columns (mm)					SecurityGuard ULTRA Cartridges†
Phases	30 x 2.1	50 x 2.1	100 x 2.1	150 x 2.1	3/pk
C18	00A-4475-AN	00B-4475-AN	00D-4475-AN	00F-4475-AN	AJ0-8782
for 2.1 mm ID					

1.7µm MidBore Columns (mm)			SecurityGuard ULTRA Cartridges†
Phases	50 x 3.0	100 x 3.0	3/pk
C18	00B-4475-YO	00D-4475-YO	AJ0-8775
for 3.0 mm ID			

†SecurityGuard Ultra Cartridges require holder, Part No.: [AJ0-9000](#)

Conclusion

The direct injection capability of the Strata®-X PRO extracted sample on the Luna HILIC LC column results in a simple, rapid identification and quantitation of GHB in whole blood. The prescribed method greatly benefits the time sensitive disposition of the assay and clean-up of whole blood matrix to provide an accurate analysis.

References

- Rachel R. McCusker. *Analysis of Gamma-Hydroxybutyrate (GHB) in urine by Gas Chromatography-Mass Spectrometry. J. of Analytical Toxicology*. Vol. 23, September 1999
- Po-Chiao Liao a. *Clinical management of GHB withdrawal delirium. J. of Formosan Medical Association* 117, 1124-1127, 2018
- Fiona J. Couper and Barry K. Logan. Determination of g-Hydroxybutyrate (GHB) in *Biological Specimens by Gas Chromatography-Mass Spectrometry. J. of Analytical Toxicology*, Vol. 24, January/ February 2000

Presston™ 1000 Positive Pressure Manifold

Part No. Description

[AH1-7033](#) Presston 1000 Positive Pressure Manifold, 96-Well Plate



Phenomenex warrants the Presston 1000 will be free of defects in materials and workmanship under normal installation, use, and maintenance for a period of 12 months following delivery. Please visit www.phenomenex.com/Presstonwarranty for complete warranty information.



APPLICATIONS

Luna[®] LC Columns

3 µm Minibore Columns (mm)				SecurityGuard [™] Cartridges (mm)	
Phases	30 x 2.0	50 x 2.0	100 x 2.0	150 x 2.0	4 x 2.0*
HILIC	00A-4449-B0	00B-4449-B0	00D-4449-B0	00F-4449-B0	AJ0-8328 /10pk

for ID: 2.0-3.0 mm

3 µm MidBore [™] and Analytical Columns (mm)				SecurityGuard Cartridges (mm)		
Phases	50 x 3.0	150 x 3.0	100 x 4.6	150 x 4.6	4 x 2.0*	4 x 3.0*
HILIC	00B-4449-Y0	00F-4449-Y0	00D-4449-E0	00F-4449-E0	AJ0-8328 /10pk	AJ0-8329 /10pk

for ID: 2.0-3.0 mm 3.2-8.0 mm

*SecurityGuard[™] Analytical Cartridges require holder, Part No.: [KJ0-4282](#)

Australia

t: +61 (0)2-9428-6444
auiinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
info@phenomenex.com

China

t: +86 400-606-8099
cninfo@phenomenex.com

Denmark

t: +45 4824 8048
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
anfrage@phenomenex.com

India

t: +91 (0)40-3012 2400
indiainfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
eireinfo@phenomenex.com

Italy

t: +39 051 6327511
italiainfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
nordicinfo@phenomenex.com

Portugal

t: +351 221 450 488
ptinfo@phenomenex.com

Singapore

t: +65 800-852-3944
sginfo@phenomenex.com

Spain

t: +34 91-413-8613
espinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20
swissinfo@phenomenex.com

Taiwan

t: +886 (0) 0801-49-1246
twinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
info@phenomenex.com

☎ All other countries/regions Corporate Office USA

t: +1 (310) 212-0555
info@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com



Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

Strata, Kinetex, and Luna are registered trademarks and SecurityGuard, MidBore, Be-Happy, and Preston are trademarks of Phenomenex. Agilent is a registered trademark of Agilent Technologies, Inc. Bioreclamation IVT is a registered trademark of Bioreclamation-IVT Holdings, LLC. SCIEEX is a registered trademark and API Triple Quad 4500 is a trademark of SCIEEX Pte. Ltd. AB SCIEEX is being used under license.

Disclaimer

Comparative separations may not be representative of all applications. Phenomenex is not affiliated with Sigma-Aldrich, Inc. or Waters Corporation. SecurityGuard is patented by Phenomenex. U.S. Patent No. 6, 162, 362

CAUTION: this patent only applies to the analytical-sized guard cartridge holder, and does not apply to SemiPrep, PREP or ULTRA holders, or to any cartridges
FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2019 Phenomenex, Inc. All rights reserved.